Skip to main content
Top
Published in: Journal of Cancer Education 6/2018

01-12-2018

Patterns of Care Related to Post-Operative Radiotherapy for Patients with Prostate Cancer among Canadian Radiation Oncologists and Urologists

Authors: Bonnie Bristow, Mohammed Aldehaim, Katija Bonin, Candice Chee Ka Lam, Stephanie J. Wan, Xingshan Cao, Ewa Szumacher

Published in: Journal of Cancer Education | Issue 6/2018

Login to get access

Abstract

The American Society for Radiation Oncology (ASTRO) and American Urological Association (AUA) developed post-prostatectomy radiotherapy (RT) guidelines to aid patient counseling on adjuvant (ART) and salvage radiotherapy (SRT). Our study compared how aware and compliant Canadian radiation oncologists and urologists are to these guidelines. Our online survey was distributed through the Canadian Association of Radiation Oncology (CARO) and Canadian Urology Association (CUA) to radiation oncologists and urologists that treat prostate cancer. We used Wilcoxon rank-sum test and Chi-square test to compare radiation oncologists and urologists. P values for significant findings are reported. A total of 128 participants responded the survey, 52 radiation oncologists, and 76 urologists. The majority (82%) of radiation oncologists had read these guidelines, compared to only 49% of urologists (p < 0.001). Radiation oncologists were more likely to recommend ART >50% for adverse pathological findings post-radical prostatectomy compared to urologists (76 vs. 51%, p = 0.011). Urologists were more likely to monitor their patient’s PSA level post-prostatectomy compared to radiation oncologists (93 vs. 77%, p = 0.016). Post-thematic analysis of open-ended questions revealed that urologists rarely refer patients to radiation oncologists for ART, with radiation oncologists confirming that they rarely receive referrals. This study demonstrates the low compliance to ASTRO/AUA guidelines. While radiation oncologists were more aware and compliant to guidelines, urologists were significantly more likely to monitor their patient’s PSA. This study highlighted the need for better communication between urologists and radiation oncologists, especially in referrals for ART, to facilitate treatment delivery that is concordant with ASTRO/AUA guidelines.
Literature
1.
go back to reference Canadian Cancer Society’s Advisory Committee on Cancer Statistics (2014) Canadian cancer statistics. Canadian Cancer Society, Toronto Canadian Cancer Society’s Advisory Committee on Cancer Statistics (2014) Canadian cancer statistics. Canadian Cancer Society, Toronto
2.
go back to reference Bolla M, van Poppel H, Tombal B et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380:2018–2027. doi:10.1016/S0140-6736(12)61253-7 CrossRefPubMed Bolla M, van Poppel H, Tombal B et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380:2018–2027. doi:10.​1016/​S0140-6736(12)61253-7 CrossRefPubMed
4.
go back to reference Wang L, Handorf E, Murphy C et al (2015) Contemporary trends in receipt of local therapy for men with clinically localized high-risk prostxate cancer. J Clin Oncol 33:111CrossRef Wang L, Handorf E, Murphy C et al (2015) Contemporary trends in receipt of local therapy for men with clinically localized high-risk prostxate cancer. J Clin Oncol 33:111CrossRef
7.
go back to reference Thompson I, Valicenti R, Albertsen P et al (2013) Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline. J Urol 190:441–449CrossRefPubMed Thompson I, Valicenti R, Albertsen P et al (2013) Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline. J Urol 190:441–449CrossRefPubMed
9.
go back to reference Hoffman K, Nguyen P, Chen M et al (2011) Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol 185:116–120CrossRefPubMed Hoffman K, Nguyen P, Chen M et al (2011) Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol 185:116–120CrossRefPubMed
10.
go back to reference Showalter T, Ohri N, Teti K et al (2012) Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys 82:233–238CrossRef Showalter T, Ohri N, Teti K et al (2012) Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys 82:233–238CrossRef
11.
go back to reference Zimmermann M, Taussky D, Delouya G, Alenizi AM, Zorn KC (2015) Radiation therapy after radical prostatectomy: a single-centre radiation oncology experience in trends of referral and treatment practices. Can Urol Assoc J 9(9–10):E608–E612. doi:10.5489/cuaj.2815 CrossRefPubMedPubMedCentral Zimmermann M, Taussky D, Delouya G, Alenizi AM, Zorn KC (2015) Radiation therapy after radical prostatectomy: a single-centre radiation oncology experience in trends of referral and treatment practices. Can Urol Assoc J 9(9–10):E608–E612. doi:10.​5489/​cuaj.​2815 CrossRefPubMedPubMedCentral
17.
go back to reference Wagner A, Ghia A, Shrieve D et al (2014) Adjuvant radiotherapy after prostatectomy: have randomized clinical trials had any impact? J Radiat Oncol Biol Phys 3:387–394CrossRef Wagner A, Ghia A, Shrieve D et al (2014) Adjuvant radiotherapy after prostatectomy: have randomized clinical trials had any impact? J Radiat Oncol Biol Phys 3:387–394CrossRef
Metadata
Title
Patterns of Care Related to Post-Operative Radiotherapy for Patients with Prostate Cancer among Canadian Radiation Oncologists and Urologists
Authors
Bonnie Bristow
Mohammed Aldehaim
Katija Bonin
Candice Chee Ka Lam
Stephanie J. Wan
Xingshan Cao
Ewa Szumacher
Publication date
01-12-2018
Publisher
Springer US
Published in
Journal of Cancer Education / Issue 6/2018
Print ISSN: 0885-8195
Electronic ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-017-1230-7

Other articles of this Issue 6/2018

Journal of Cancer Education 6/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine